Wells Fargo & Company Dyne Therapeutics, Inc. Transaction History
Wells Fargo & Company
- $433 Billion
- Q4 2024
A detailed history of Wells Fargo & Company transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 38,754 shares of DYN stock, worth $445,671. This represents 0.0% of its overall portfolio holdings.
Number of Shares
38,754
Previous 25,077
54.54%
Holding current value
$445,671
Previous $900,000
1.44%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding DYN
# of Institutions
213Shares Held
103MCall Options Held
135KPut Options Held
435K-
Atlas Venture Life Science Advisors, LLC8.02MShares$92.2 Million31.16% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$85 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X07.38MShares$84.9 Million0.09% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.7MShares$77.1 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.38MShares$73.4 Million2.43% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $595M
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...